PER-012-03已完成未知
AN EXTENSION OF 12 MONTHS FOR: A RANDOMIZED, DOUBLE-BLIND, DOUBLE SIMULATOR, PARALLEL GROUP, MULTICENTRIC STUDY TO EVALUATE AND COMPARE THE EFFECTS OF ALENDRONATE AND RISEDRONATE ON BONE MINERAL DENSITY IN POSTMENUPAUSIC WOMEN WITH OSTEOPOROSIS (INTERNATIONAL FOSAMAX COMPARISON TESTS AND ACTONEL: FACT (BY ITS ACRONYMS IN ENGLISH) -INTERNATIONAL)
MERCK SHARP & DOHME PERU S.R.L.,0 个研究点目标入组 0 人开始时间: 2003年3月11日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 0（—）
入选标准
- •The participant is a patient of external consultation, who resides in the community,>
- •40 years (> 25 if it is menopausal due to a surgical procedure) and postmenopausal for at least 6 months, who have osteoporosis.
- •The patient is in good health according to her medical history, physical examination and laboratory selection evaluation, which allows her to complete the test without serious co-morbid events.
排除标准
- •a. The patient is mentally or legally incapacitated or otherwise unable
- •to give informed consent.
- •b. The patient is a pregnant woman or who is breastfeeding or a woman in
- •potentially fertile.
- •c. The patient has participated in another therapeutic trial with a compound in investigation within 30 days prior to randomization.
- •d. The patient intends to move during the next year making the
- •follow-up is impractical.
- •e. The patient has a history of hypersensitivity to any component of
- •Alendronate tablets or risedronate tablets.
研究者
相似试验
已完成
不适用
AN EXTENSION OF 12 MONTHS FOR: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFECTIVENESS OF MK-0822 (KATEATE-K INHIBITOR) IN THE TREATMENT OF POST-MENOPAUSAL WOMEN WITH OSTEOPOROSIS-M80M80PER-074-07MERCK SHARP & DOHME PERU S.R.L.,
已完成
不适用
A 24-MONTH EXTENSION FOR: A RANDOMIZED, DOUBLE BLIND, CONTROLLED PLACEBO STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFECTIVENESS OF MK-0822 (KATEPSIN-K INHIBITOR) IN THE TREATMENT OF POST-MENOPAUSE WOMEN WITH OSTE-M819M819PER-139-08MERCK SHARP & DOHME PERU S.R.L.,
进行中（未招募）
1 期
A 24-Month Extension to: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Efficacy of MK-0822 (Cathepsin-K Inhibitor) in the Treatment of Postmenopausal Women with Osteoporosis - Cat-K 11b Osteoporosis StudyMedDRA version: 14.1 Level: PT Classification code 10031285 Term: Osteoporosis postmenopausal System Organ Class: 10028395 - Musculoskeletal and connective tissue disordersPostmenopausal OsteoporosisEUCTR2005-001511-22-GBMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.399
进行中（未招募）
1 期
Comparison of efficacy of masitinib versus placebo in the treatment of Crohn's diseaseCrohn's diseaseEUCTR2012-004222-25-SKAB Science450
进行中（未招募）
1 期
Comparison of efficacy of masitinib versus placebo in the treatment of Crohn's diseaseMedDRA version: 18.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersCrohn's diseaseEUCTR2012-004222-25-GRAB Science450